Patient group input submissions: Omalizumab (Xolair) for asthma, severe persistent
Questionnaires were promoted via several Canadian respiratory health agencies to asthma patients or those suffering with severe, persistent asthma-related symptoms to gather input on the effectiveness of omalizumab in the treatment of the disease
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 2017 Sep
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Questionnaires were promoted via several Canadian respiratory health agencies to asthma patients or those suffering with severe, persistent asthma-related symptoms to gather input on the effectiveness of omalizumab in the treatment of the disease |
|---|---|
| Physical Description: | 1 PDF file (13 pages) illustrations |